Clinical trials
Relapsed or Refractory Multiple Myeloma (RRMM) clinical trials
Below are recruiting relapsed or refractory multiple myeloma (rrmm) clinical trials, each written for real people, not researchers. We’re tracking 1,249 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06404528Recruiting
Low-dose chemo under low blood sugar for advanced solid tumors
This trial tests whether giving low-dose chemotherapy while your blood sugar is low can help treat advanced solid tumors that have stopped responding to standard treatments. It aims to see if this approach is safe and effective.
Wuxi, JiangsuAges 18–75 - NCT06346912RecruitingEarly Phase 1
CAR-T cell therapy for relapsed B-cell blood cancers
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT06299553Recruiting
Study of tafasitamab with lenalidomide for relapsed DLBCL patients
This study looks at how well a combination of two drugs, tafasitamab and lenalidomide, works for people with a type of lymphoma (DLBCL) that has come back or hasn't responded to treatment. After the combination, patients continue with tafasitamab alone. This is for patients who cannot have a stem cell transplant.
MilanAges 18 years+ - NCT06430502Recruiting
Cancer vaccine plus immunotherapy for advanced solid tumors
This trial tests a cancer vaccine (called TTV) combined with a PD-1 inhibitor (a type of immunotherapy) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this new combination helps shrink tumors or slow cancer growth.
Wuxi, JiangsuAges 18–85 - NCT05868395RecruitingPhase 2
Treating relapsed mantle cell lymphoma with three drug combination
This Phase 2 study tests how well polatuzumab combined with bendamustine and rituximab works for mantle cell lymphoma that has come back or not responded. It may help shrink tumors and improve disease control, especially after prior treatment with ibrutinib.
ViennaAges 18–100 - NCT06445803RecruitingPhase 1
CAR-T therapy for adults with certain blood cancers
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
Nanchang, JiangxiAges 18 years+ - NCT07838714RecruitingPhase 1
Cord blood CAR-T cells for relapsed B-cell leukemia
This trial tests a new type of personalized cell therapy using your own immune cells (called CAR-T cells) that are designed to find and attack leukemia cells that have certain markers (CD19 and CD22). It is for people whose leukemia has returned or not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06503107RecruitingPhase 1/Phase 2
Nanobody-based CAR-T cells for multiple myeloma
This trial tests a new type of CAR-T cell therapy that targets a protein called BCMA on your myeloma cells. It is for people with multiple myeloma that has not responded to or has come back after several prior treatments.
Wuhan, HubeiAges 18–75 - NCT07800936RecruitingPhase 1
Injecting drug HP007 for advanced solid tumors that stopped responding to treatment
This trial tests an injected drug directly into tumors for people with advanced solid tumors like breast, head and neck, melanoma, prostate, or liver cancer that have not responded to standard treatments. It may help shrink tumors or slow their growth.
Changchun, JilinAges 18–75 - NCT05504772Recruiting
Personalized genetic testing for children with cancer
This trial studies how personalized (tailored) genetic testing can help guide care for children with cancer. It may help match treatment choices to each child’s genetic risk, and it includes optional return of germline (inherited) test results.
AdelaideAges birth–25 years - NCT06515262Recruiting
Testing anti-BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Kunming, Kunming, YunnanAges 18–75 - NCT06514313RecruitingPhase 2
Study of a drug combo for children with returning soft tissue sarcoma
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
Guangzhou, GuangdongAges 2–21 - NCT06517004RecruitingPhase 1
Study of JWCAR201 for relapsed or refractory large B-cell lymphoma
This trial tests a new cell therapy called JWCAR201 for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to at least two prior treatments. The goal is to see if this treatment can help when standard options have stopped working.
ShanghaiAges 18 years+ - NCT03676504RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
HeidelbergAges 3 years+ - NCT06537843RecruitingPhase 2
Venetoclax, cytarabine and metformin for AML
This trial tests a combination of three drugs – venetoclax, cytarabine, and metformin – for adults with AML who cannot receive standard high-dose chemotherapy. It aims to see if this gentler mix can help control the leukemia with fewer side effects.
BelémAges 18 years+ - NCT07783100RecruitingPhase 2
Combination treatment for relapsed or refractory acute myeloid leukemia
This study tests a combination of three drugs (venetoclax, chidamide, and chiglitazar) for people with acute myeloid leukemia (AML) that has not responded to standard treatment or has returned. The goal is to see if this combination can help control the leukemia and is safe.
Xiamen, FujianAges 18 years+ - NCT06554600RecruitingPhase 2
Study of zanubrutinib plus polatuzumab, bendamustine, and rituximab for relapsed DLBCL
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
Hanzhou, ZhejiangAges 18–75 - NCT06541327Recruiting
Cell therapy for returning lymphoma study
This study collects data from adults with lymphoma that has come back or not improved after treatment, who have received or are receiving special cell therapies. The goal is to learn more about how these treatments work in real life.
ShanghaiAges 18 years+ - NCT06479356RecruitingPhase 2
CAR T-cell therapy for relapsed large B-cell lymphoma
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07767630RecruitingEarly Phase 1
Targeted radiation therapy for relapsed neuroblastoma
This trial tests a new type of targeted radiation treatment for children and adults with neuroblastoma that has come back or not responded to other treatments. The radiation is attached to a substance that seeks out neuroblastoma cells, aiming to destroy them while limiting harm to healthy tissue.
Chengdu, SichuanAges 1–100 - NCT04838652RecruitingPhase 2
Pembrolizumab with salvage chemotherapy for Hodgkin lymphoma
This Phase 2 study tests whether pembrolizumab combined with salvage (second-line) chemotherapy can treat people whose classical Hodgkin lymphoma has either come back after initial treatment or did not respond to initial treatment. You may benefit if you have first-relapsed or refractory classical Hodgkin lymphoma and meet other study rules.
CologneAges 18–65 - NCT05830123RecruitingPhase 2
Test drug HS-20093 for osteosarcoma after earlier treatment
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
BeijingAges 18 years+ - NCT06450067Recruiting
Inaticabtagene Autoleucel for Relapsed or Refractory ALL
This trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It may offer a new option for people who need additional treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+
Hear when a new Relapsed or Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma (rrmm)?
- Yes. Clin2 currently lists 1,249 recruiting relapsed or refractory multiple myeloma (rrmm) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma (rrmm) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma (rrmm) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.